<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="177364">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786318</url>
  </required_header>
  <id_info>
    <org_study_id>010411</org_study_id>
    <nct_id>NCT00786318</nct_id>
  </id_info>
  <brief_title>Ziprasidone vs Standard Therapy for Agitated Patients in the ED</brief_title>
  <official_title>Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine if ziprasidone is superior to standard therapies in
      the emergency department treatment of the acutely agitated patient. The primary outcome will
      be the length of time taken until the patient is ready to be evaluated by the psychiatric
      service, or until a disposition is made.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>length of time from triage until patient is either ready to be seen by psychiatry or is ready to have a disposition made</measure>
    <time_frame>During ED stay</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of time taken to sedate patient</measure>
    <time_frame>Ed visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time spent in restraints</measure>
    <time_frame>ED visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness of the therapy</measure>
    <time_frame>ED visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Psychosis</condition>
  <condition>Agitation</condition>
  <condition>Delirium</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
    <description>ziprasidone 20mg IM</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Haldol 5mg/ Ativan 2mg IM</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acutely agitated

          -  Requires chemical sedation

        Exclusion Criteria:

          -  Physician preference for a specific chemical sedative

          -  Known allergy to any study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The George Washington University Medical Center, Dept of Emergency Medicine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brown J. The spectrum of informed consent in emergency psychiatric research. Ann Emerg Med. 2006 Jan;47(1):68-74. Epub 2005 Nov 17.</citation>
    <PMID>16387220</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <lastchanged_date>June 18, 2010</lastchanged_date>
  <firstreceived_date>November 5, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Jeremy Brown</name_title>
    <organization>Dept of Emergency Medicine, The George Washington University Medical Center</organization>
  </responsible_party>
  <keyword>Psychosis</keyword>
  <keyword>Agitation</keyword>
  <keyword>Delirium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
